HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III ...

A subgroup analysis from the FOCUS trial presented at ESMO 2024 demonstrated similar outcomes in overall survival, overall ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...

We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

And at the time, durable remissions were seen in many patients. The data that we presented at ESMO this year showed the ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial ...

ECHO, a proprietary diagnostic for detection of ecDNA amplified oncogenes In September, analytical validation data was presented at the European Society for Medical Oncology (ESMO) Congress for the ...

Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...

About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking ...

NIAGARA received a warm reception when it was presented at the ESMO cancer congress, with discussant Petros Grivas from the University of Washington and Fred Hutchinson Cancer Center in Seattle ...